- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT04901884
PET/MR pre- en postradiotherapie voor evaluatie van cardiopulmonale disfunctie
Verkennende evaluatie van gelijktijdige cardiale PET/MR, metabolomische markers en circulerend DNA als mogelijke prognostische markers bij het identificeren van patiënten die voorbijgaande of permanente cardiopulmonale disfuncties ontwikkelen na radiotherapie
Radiotherapy (RT) is a well-known and established therapy or adjuvant therapy for the treatment of thoracic cancer It uses a high energy radiation from x-rays, gamma rays and other charged particles that assist in damaging the cancer DNA.
PET/MR as imaging biomarkers for cardiopulmonary dysfunction with a focus on Pulmonary hypertension (PH).
Despite the measures taken to reduce the total radiation dose and to limit the radiation to normal tissues, there is evidence of transient or permanent radiotherapy induced myocardial and pulmonary dysfunction leading to PH in patients who receive radiotherapy above a certain threshold of received dose.
To be able to Demonstrate correlation of combined PET/MR and plasma metabolomics markers in patients at risk of developing cardiopulmonary disfunction after RT.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
RT is a well-known and established therapy or adjuvant therapy for the treatment of thoracic malignancies (breast cancer, lung cancer, lymphoma and others). It usually uses high energy radiation from x-rays, gamma rays or other charged particles to induce DNA damage in malignant cells. Despite the measures taken to reduce the total radiation dose and to limit the radiation to normal tissues, the signs and symptoms of radiation induced cardiopulmonary dysfunction (RICPD) still persist. However, in the majority of cases, it remains unclear which cardiopulmonary damage is the main /leading cause for the clinical symptoms the patients are experiencing.
Hybrid PET/MRI is a promising technique that allows for truly simultaneous molecular, anatomic and functional imaging of the cardiopulmonary system. The simultaneity is an important aspect in this proposed study since only parameters measured at the same time in PET and MR can be used for an integrated, multimodality parameter for possible detection and prognostication of the different underlying processes of cardiopulmonary dysfunction after RT. Furthermore, certain PET-uptake of the RV have to be corrected for RV mass which is only possible with concomitant anatomical imaging. MR imaging and PET at different time point are not accurately reflective of the underlying pathophysiological pathways and metabolic state at the specific time points pre- and post radiotherapy. To our knowledge, there are no online publications of its use in the diagnosis and prognostication of cardiopulmonary dysfunction after RT and specifically PH.
Studietype
Inschrijving (Geschat)
Fase
- Niet toepasbaar
Contacten en locaties
Studiecontact
- Naam: Patrick Veit-Haibach, MD
- Telefoonnummer: 6085 416-340-4800
- E-mail: Patrick.Veit-Haibach@uhn.ca
Studie Contact Back-up
- Naam: Andrew Hope, MD
- Telefoonnummer: 416-946-2124
- E-mail: Andrew.Hope@rmp.uhn.ca
Studie Locaties
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2M9
- Werving
- University Health Network
-
Contact:
- Patrick Veit-Haibach
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Age ≥18 years
- Biopsy or otherwise clinically proven thoracic malignant mass which is intended to be treated with radio(chemo)therapy
- Intention to treat with radio(chemo)therapy with incidental cardiac irradiation of at least 25Gy.
- A negative urine or serum pregnancy test within the two week interval immediately prior to imaging, in women of child-bearing age.
- Ability to provide written informed consent to participate in the study (for all components of the trial: imaging with cardiac PET/MR, blood sampling for plasma metabolomics and circulating DNA).
Exclusion Criteria:
- Contraindication for MR as per current institutional guidelines.
- Contraindication for Gadolinium injection as per current institutional guidelines.
- Inability to lie supine for at least 45 minutes.
- Any patient who is pregnant or breastfeeding.
- Any patient with known hypersensitivity to 18F-FDG.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Diagnostisch
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: One arm / exploratory study
Injection of 18F-FDG.The 18F-FDG cardiac PET-MR scanning visit will take up to 1.5 hours. |
(18F) Fluorodeoxyglucose (FDG) will be administered by intravenous injection at a dose of 4-5 MBq/kg. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change of FDG uptake of heart
Tijdsspanne: at 4 weeks prior to radiotherapy, and at 6-10 weeks after completion of radiotherapy
|
FDG uptake of the left and right ventricles of heart will be measured and compared in PETMRI scans |
at 4 weeks prior to radiotherapy, and at 6-10 weeks after completion of radiotherapy
|
|
Change of FDG uptake of lungs
Tijdsspanne: at 4 weeks prior to radiotherapy, and at 6-10 weeks after completion of radiotherapy
|
FDG uptake of left and right ratios within the lungs in PETMRI scans |
at 4 weeks prior to radiotherapy, and at 6-10 weeks after completion of radiotherapy
|
|
Change of the heart function
Tijdsspanne: at 4 weeks prior to radiotherapy, and at 6-10 weeks after completion of radiotherapy
|
MRI of ventricular volumes in PETMRI scans |
at 4 weeks prior to radiotherapy, and at 6-10 weeks after completion of radiotherapy
|
|
Change of the lung perfusion
Tijdsspanne: before radiotherapy and up to 16 weeks after completion of radiotherapy
|
Percentage of the perfused/ventilated lung segments will be evaluated and compared pre and post therapy by SPECT scans |
before radiotherapy and up to 16 weeks after completion of radiotherapy
|
Medewerkers en onderzoekers
Onderzoekers
- Hoofdonderzoeker: Patrick Veit-Haibach, MD, University Health Network, Toronto
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- 18-5879
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .